|
US4476116A
(en)
|
1982-12-10 |
1984-10-09 |
Syntex (U.S.A.) Inc. |
Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
|
|
US5116817A
(en)
|
1982-12-10 |
1992-05-26 |
Syntex (U.S.A.) Inc. |
LHRH preparations for intranasal administration
|
|
US5244792A
(en)
|
1984-04-06 |
1993-09-14 |
Chiron Corporation |
Expression of recombinant glyoprotein B from herpes simplex virus
|
|
JPH0668B2
(ja)
|
1985-08-30 |
1994-01-05 |
財団法人化学及血清療法研究所 |
単純ヘルペスウイルス遺伝子が組込まれた組換えプラスミド
|
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
US5804413A
(en)
|
1992-07-31 |
1998-09-08 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Herpes simplex virus strains for gene transfer
|
|
US6084067A
(en)
|
1993-07-26 |
2000-07-04 |
Dana-Farber Cancer Institute |
CTLA4/CD28 ligands and uses therefor
|
|
GB9415369D0
(en)
|
1994-07-29 |
1994-09-21 |
Lynxvale Ltd |
Mutant virus
|
|
US5855887A
(en)
|
1995-07-25 |
1999-01-05 |
The Regents Of The University Of California |
Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US6051227A
(en)
|
1995-07-25 |
2000-04-18 |
The Regents Of The University Of California, Office Of Technology Transfer |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
US6071742A
(en)
|
1997-03-05 |
2000-06-06 |
Board Of Regents Of The University Of Nebraska |
Coxsackie virus as a vector for delivery of anti-inflammatory cytokines
|
|
WO1998040475A1
(en)
|
1997-03-11 |
1998-09-17 |
Abbott Laboratories |
Human matrix metalloprotease gene, proteins encoded therefrom and methods of using same
|
|
WO1998042752A1
(en)
|
1997-03-21 |
1998-10-01 |
Brigham And Women's Hospital Inc. |
Immunotherapeutic ctla-4 binding peptides
|
|
US6391452B1
(en)
|
1997-07-18 |
2002-05-21 |
Bayer Corporation |
Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
|
|
WO1999006583A1
(en)
|
1997-07-31 |
1999-02-11 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Targeted hsv vectors
|
|
US6989435B2
(en)
|
1997-09-11 |
2006-01-24 |
Cambridge University Technical Services Ltd. |
Compounds and methods to inhibit or augment an inflammatory response
|
|
DE69831754T2
(de)
|
1997-12-17 |
2006-06-29 |
Immunex Corp., Thousand Oaks |
Zelloberflächenglycoproteinen zusammenhang mit menschlicher b zell lymphomen - ulbp, dns und polypeptiden
|
|
US6506559B1
(en)
|
1997-12-23 |
2003-01-14 |
Carnegie Institute Of Washington |
Genetic inhibition by double-stranded RNA
|
|
KR100508289B1
(ko)
|
1998-04-21 |
2005-08-17 |
마이크로메트 에이지 |
Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도
|
|
US6455677B1
(en)
|
1998-04-30 |
2002-09-24 |
Boehringer Ingelheim International Gmbh |
FAPα-specific antibody with improved producibility
|
|
EP0953639A1
(en)
|
1998-04-30 |
1999-11-03 |
Boehringer Ingelheim International GmbH |
FAPalpha-specific antibody with improved producibility
|
|
EP1002864A1
(en)
|
1998-11-10 |
2000-05-24 |
Universita' degli studi di Bologna |
HIgR and related V domain for the manufacture of a medicament for preventing or treating HSV-1, HSV-2 and BHV infections
|
|
EE05627B1
(et)
|
1998-12-23 |
2013-02-15 |
Pfizer Inc. |
CTLA-4 vastased inimese monoklonaalsed antikehad
|
|
HRP20130077A2
(hr)
|
1998-12-23 |
2013-07-31 |
Pfizer Inc. |
Humana monoklonalna protutjela za ctla-4
|
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
|
CN102766210B
(zh)
|
1999-08-24 |
2015-07-08 |
E.R.施贵宝&圣斯有限责任公司 |
人ctla-4抗体及其应用
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
US6897057B1
(en)
|
1999-08-31 |
2005-05-24 |
The General Hospital Corporation |
Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression
|
|
EP1235842A4
(en)
|
1999-10-15 |
2003-04-23 |
Univ Massachusetts |
Rna interference pathway genes as tools for targeted genetic interference
|
|
EP1261376A1
(en)
|
2000-01-27 |
2002-12-04 |
Genetics Institute, LLC |
Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
|
|
EP1268550A2
(en)
|
2000-03-17 |
2003-01-02 |
Boehringer Ingelheim Pharma KG |
Human fap-alpha-specific antibodies
|
|
ATE450621T2
(de)
|
2000-03-30 |
2009-12-15 |
Whitehead Biomedical Inst |
Mediatoren von rns-interferenz, die rns- sequenzspezifisch sind
|
|
KR100872437B1
(ko)
|
2000-12-01 |
2008-12-05 |
막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. |
Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
|
|
ES2366608T3
(es)
|
2001-03-27 |
2011-10-21 |
The General Hospital Corporation |
Vectores víricos y su uso en métodos terapéuticos.
|
|
ATE434624T1
(de)
|
2001-10-04 |
2009-07-15 |
Immunex Corp |
Ul16-bindungsprotein 4
|
|
KR100900249B1
(ko)
|
2001-12-07 |
2009-05-29 |
포항공과대학교 산학협력단 |
ＳＩＶｍａｃ239의 면역원성 플라스미드 및 이들을 함유한ＡＩＤＳ ＤＮＡ 백신
|
|
ES2384168T3
(es)
|
2002-04-12 |
2012-07-02 |
Medarex, Inc. |
Procedimientos de tratamiento usando anticuerpos CTLA-4
|
|
PT1537878E
(pt)
|
2002-07-03 |
2010-11-18 |
Ono Pharmaceutical Co |
Composições de imunopotenciação
|
|
US8927251B2
(en)
|
2002-10-07 |
2015-01-06 |
The University Of Chicago |
Targeting of herpes simplex virus to specific receptors
|
|
KR20110017020A
(ko)
|
2002-10-17 |
2011-02-18 |
젠맵 에이/에스 |
Ｃｄ20에 대한 인간 모노클로날 항체
|
|
WO2004072286A1
(ja)
*
|
2003-01-23 |
2004-08-26 |
Ono Pharmaceutical Co., Ltd. |
ヒトｐｄ−１に対し特異性を有する物質
|
|
US20060240024A1
(en)
|
2003-02-28 |
2006-10-26 |
The Johns Hopkins University |
T cell regulation
|
|
CA2518782A1
(en)
|
2003-03-12 |
2004-09-23 |
Duke University |
Oligonucleotide mimetics
|
|
US7473418B2
(en)
|
2004-03-25 |
2009-01-06 |
Cell Genesys, Inc. |
Pan cancer oncolytic vectors and methods of use thereof
|
|
CA2560919A1
(en)
|
2004-03-26 |
2005-10-06 |
Pfizer Products Inc. |
Uses of anti-ctla-4 antibodies
|
|
EP1793851B1
(en)
|
2004-08-20 |
2016-10-05 |
Viralytics Limited |
Methods and compositions for treatment of hematologic cancers
|
|
EP1793858A4
(en)
|
2004-09-08 |
2008-12-10 |
Univ Ohio State Res Found |
HUMAN MONOCLONAL ANTI-CTLA4 ANTIBODIES FOR CANCER TREATMENT
|
|
AU2005302408B2
(en)
|
2004-10-28 |
2012-08-09 |
The Government of the United States of America as represented by the Department of Veterans Affairs |
Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
|
|
WO2006074526A1
(en)
|
2005-01-17 |
2006-07-20 |
Viralytics Limited |
Method and composition for treatment of neoplasms
|
|
ES2564823T3
(es)
|
2005-05-27 |
2016-03-29 |
Ospedale San Raffaele S.R.L. |
Vector génico que comprende miARN
|
|
KR101510065B1
(ko)
|
2005-06-08 |
2015-04-07 |
다나-파버 캔서 인스티튜트 인크. |
예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물
|
|
CA2612241C
(en)
|
2005-07-01 |
2018-11-06 |
Medarex, Inc. |
Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
|
|
US8980246B2
(en)
|
2005-09-07 |
2015-03-17 |
Sillajen Biotherapeutics, Inc. |
Oncolytic vaccinia virus cancer therapy
|
|
SI1976886T1
(sl)
|
2005-12-16 |
2015-03-31 |
Amgen Research (Munich) Gmbh |
Sredstva in postopki za zdravljenje tumorskih bolezni
|
|
JP2009521474A
(ja)
|
2005-12-21 |
2009-06-04 |
メディミューン，エルエルシー |
ＥｐｈＡ２ＢｉＴＥ分子およびその使用
|
|
EP1806365A1
(en)
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
|
|
US9868961B2
(en)
|
2006-03-30 |
2018-01-16 |
The Regents Of The University Of California |
Methods and compositions for localized secretion of anti-CTLA-4 antibodies
|
|
WO2007137328A1
(en)
|
2006-05-26 |
2007-12-06 |
Apollo Life Sciences Limited |
An isolated il-12 molecule or chimeric molecules thereof
|
|
CN101104640A
(zh)
|
2006-07-10 |
2008-01-16 |
苏州大学 |
抗人pd-l1单克隆抗体制备及应用
|
|
JP2008066402A
(ja)
|
2006-09-05 |
2008-03-21 |
Fujifilm Corp |
撮像素子および撮像装置
|
|
CN102026645B
(zh)
*
|
2006-09-15 |
2016-01-27 |
渥太华医院研究机构 |
溶瘤弹状病毒
|
|
EP2125032A4
(en)
|
2007-02-20 |
2011-02-23 |
Mayo Foundation |
CANCER TREATMENT WITH VIRAL NUCLEIC ACID
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
WO2008134878A1
(en)
*
|
2007-05-04 |
2008-11-13 |
University Health Network |
Compositions and methods for cancer treatment
|
|
CA2687301C
(en)
|
2007-05-09 |
2016-08-23 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Synthetic herpes simplex viruses type-1 for treatment of cancers
|
|
US9416165B2
(en)
|
2007-10-26 |
2016-08-16 |
The Regents Of The University Of California |
Methods of inhibiting viral replication and improving T cell function employing soluble Tim-3 inhibitors
|
|
US8263073B2
(en)
|
2008-02-04 |
2012-09-11 |
Medarex, Inc. |
Anti-CTLA-4 antibodies with reduced blocking of binding of CTLA-4 to B7 and uses thereof
|
|
WO2009111892A1
(en)
|
2008-03-14 |
2009-09-17 |
Ottawa Health Research Institute |
Microrna mediated oncolytic targeting
|
|
NO2700405T3
(enExample)
|
2008-05-29 |
2018-09-01 |
|
|
|
EP2307033A4
(en)
|
2008-05-29 |
2012-06-13 |
Gen Hospital Corp |
USE OF ONCOLYTIC HERPESVIRUS FOR THE KILLING OF CANCER STEM CELLS
|
|
GB0810912D0
(en)
|
2008-06-13 |
2008-07-23 |
Inst Animal Health Ltd |
Vector
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
PL2342226T3
(pl)
|
2008-09-26 |
2017-01-31 |
Dana-Farber Cancer Institute, Inc. |
Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania
|
|
EP4209510B1
(en)
|
2008-12-09 |
2024-01-31 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
EP3192811A1
(en)
|
2009-02-09 |
2017-07-19 |
Université d'Aix-Marseille |
Pd-1 antibodies and pd-l1 antibodies and uses thereof
|
|
US8569065B2
(en)
|
2009-03-13 |
2013-10-29 |
Egen, Inc. |
Compositions and methods for the delivery of biologically active RNAs
|
|
ES2385251B1
(es)
*
|
2009-05-06 |
2013-05-06 |
Fundació Privada Institut D'investigació Biomèdica De Bellvitge |
Adenovirus oncolíticos para el tratamiento del cáncer.
|
|
US20100297072A1
(en)
|
2009-05-19 |
2010-11-25 |
Depinho Ronald A |
Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
|
|
AU2011237630B2
(en)
|
2010-04-06 |
2016-01-21 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of CD274/PD-L1 gene
|
|
CA2795695A1
(en)
|
2010-04-09 |
2011-10-13 |
The University Of Tokyo |
Microrna-controlled recombinant vaccinia virus and use thereof
|
|
US9593347B2
(en)
|
2010-04-16 |
2017-03-14 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors
|
|
CA2802344C
(en)
|
2010-06-18 |
2023-06-13 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
|
|
WO2012006181A2
(en)
|
2010-06-29 |
2012-01-12 |
Mount Sinai School Of Medicine |
Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer
|
|
SG187746A1
(en)
|
2010-08-13 |
2013-03-28 |
Roche Glycart Ag |
Anti-fap antibodies and methods of use
|
|
GB201103955D0
(en)
|
2011-03-09 |
2011-04-20 |
Antitope Ltd |
Antibodies
|
|
SI2699264T1
(en)
|
2011-04-20 |
2018-08-31 |
Medimmune Llc |
Antibodies and other molecules that bind b7-h1 and pd-1
|
|
WO2013006490A2
(en)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to tim3
|
|
HRP20182194T1
(hr)
*
|
2011-09-08 |
2019-02-22 |
New York University |
Onkolitički herpes simpleks virus i njegova terapeutska uporaba
|
|
US11951157B2
(en)
|
2011-10-11 |
2024-04-09 |
Universitat Zurich |
Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody
|
|
EP2591796A1
(en)
|
2011-11-10 |
2013-05-15 |
Universität Zürich |
Combination medicament comprising IL-12 and an anti-CTLA-4 ligand for tumor therapy
|
|
CA2850575C
(en)
|
2011-10-11 |
2020-12-15 |
Universitat Zurich Prorektorat Mnw |
Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy
|
|
CA2850245C
(en)
|
2011-10-17 |
2020-04-28 |
Herlev Hospital |
Pd-l1 based immunotherapy
|
|
US20130156808A1
(en)
|
2011-11-22 |
2013-06-20 |
Stipan Jonjic |
Vaccine comprising beta-herpesvirus
|
|
US9624298B2
(en)
|
2011-11-28 |
2017-04-18 |
Merck Patent Gmbh |
Anti-PD-L1 antibodies and uses thereof
|
|
DK2806883T3
(da)
|
2012-01-25 |
2019-07-22 |
Dnatrix Inc |
Biomarkører og kombinationsterapier under anvendelse af onkolytisk virus og immunomodulation
|
|
AU2013267161A1
(en)
|
2012-05-31 |
2014-11-20 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind PD-L1
|
|
US20150250837A1
(en)
*
|
2012-09-20 |
2015-09-10 |
Morningside Technology Ventures Ltd. |
Oncolytic virus encoding pd-1 binding agents and uses of the same
|
|
AR092745A1
(es)
|
2012-10-01 |
2015-04-29 |
Univ Pennsylvania |
Composiciones que comprenden un dominio de union anti-fap y metodos para hacer blanco en celulas estromales para el tratamiento del cancer
|
|
CN105407902A
(zh)
*
|
2013-03-05 |
2016-03-16 |
贝勒医学院 |
溶瘤病毒
|
|
JP6420776B2
(ja)
*
|
2013-03-05 |
2018-11-07 |
ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ |
免疫療法のためのエンゲージャー細胞
|
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
|
DK3461491T3
(da)
|
2013-04-18 |
2025-02-03 |
Tilt Biotherapeutics Oy |
Forbedret adoptiv celleterapi
|
|
US20160163211A1
(en)
|
2013-05-16 |
2016-06-09 |
Pearson Education, Inc. |
Accessible content publishing engine
|
|
KR102490462B1
(ko)
|
2013-10-28 |
2023-01-19 |
유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 |
종양분해성 hsv 벡터
|
|
WO2015127501A1
(en)
|
2014-02-27 |
2015-09-03 |
Viralytics Limited |
Combination method for treatment of cancer
|
|
EP3552615B8
(en)
*
|
2014-07-16 |
2022-03-02 |
Transgene |
Oncolytic virus for expression of immune checkpoint modulators
|
|
BR112017006468A2
(pt)
|
2014-10-08 |
2017-12-19 |
Hoffmann La Roche |
anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer
|
|
CA2973720A1
(en)
*
|
2015-01-14 |
2016-07-21 |
Compass Therapeutics Llc |
Multispecific immunomodulatory antigen-binding constructs
|
|
CN108135934B
(zh)
|
2015-10-19 |
2024-09-10 |
永恒生物科技股份有限公司 |
通过组合疗法治疗实体或淋巴肿瘤的方法
|
|
EA201891022A1
(ru)
*
|
2015-12-17 |
2019-01-31 |
Псайоксус Терапьютикс Лимитед |
Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела
|
|
WO2017118866A1
(en)
*
|
2016-01-08 |
2017-07-13 |
Replimune Limited |
Engineered virus
|
|
ES2919953T3
(es)
|
2016-01-27 |
2022-07-29 |
Oncorus Inc |
Vectores víricos oncolíticos y usos de los mismos
|
|
ES3041500T3
(en)
|
2016-03-10 |
2025-11-12 |
Cg Oncology Inc |
Methods of treating solid tumors by combination therapy
|
|
CN109983121A
(zh)
|
2016-06-30 |
2019-07-05 |
昂克诺斯公司 |
治疗性多肽的假型化溶瘤病毒递送
|
|
WO2018026872A1
(en)
|
2016-08-01 |
2018-02-08 |
Virogin Biotech Canada Ltd |
Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules
|
|
US11590184B2
(en)
|
2016-08-09 |
2023-02-28 |
Turnstone Limited Partnership |
Oncolytic rhabdovirus expressing IL12
|
|
TW201825674A
(zh)
|
2016-09-09 |
2018-07-16 |
美商艾斯合顧問有限公司 |
表現雙特異性接合分子的溶瘤病毒
|
|
US20190275092A1
(en)
|
2016-11-01 |
2019-09-12 |
Dnatrix, Inc. |
Combination therapy for treatment of brain cancers
|
|
US11298420B2
(en)
|
2016-12-21 |
2022-04-12 |
Memgen, Llc |
Armed oncolytic viruses
|
|
JP2020504767A
(ja)
|
2016-12-21 |
2020-02-13 |
メムゲン，エルエルシー |
武装した複製可能な腫瘍溶解性アデノウイルス
|
|
GB201700350D0
(en)
|
2017-01-09 |
2017-02-22 |
Replimune Ltd |
Altered virus
|
|
EP3731850A4
(en)
|
2017-12-29 |
2021-12-01 |
Oncorus, Inc. |
ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
|